Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

DSP analysis by treatment response showed higher expression of CD56 and CD20 in the immune and tumor compartments in R. Conclusions: This is an ongoing prospective study that is expected to drive ...

NRAS mutations, present in 15% to 25% of melanomas, drive aggressive cancer growth that resists current treatments. It is crucial to find new ways to fight this, according to Sanjay Premi, PhD, ...

Ajami’s team, alongside collaborators at Kanvas Bio, have developed a live biotherapeutic agent composed of a bacterial consortium that aims to optimize the gut microbiome of patients with melanoma.

Schematic illustration of the preparation route and anti-tumor mechanism of pLCGM-OVA. (Image: LI Qingdong) (click on image to enlarge) Melanoma remains a clinical challenge largely due to its strong ...

While the scRNA-seq analysis of melanoma tissue and RT-PCR analysis of EMT gene expression in isolated keratinocytes provide evidence that a subpopulation of host keratinocytes upregulates Twist and ...

Reporting on their studies in Cell, “ Sex-dependent effects in the aged melanoma tumor microenvironment influence invasion and resistance to targeted therapy,” the team, co-led by Yash Chhabra ...

Meanwhile, the CNIO’s Microenvironment and Metastasis Group, led by Héctor Peinado, has discovered what could become one of the first treatments against melanoma metastasis in its early stages.

Abstract. Purpose: Acral melanoma (AM) is the most common subtype in Chinese melanoma patients with a very poor prognosis. However, our understanding of the disease pathogenesis and molecular ...